Conditions: Hepatitis C Virus Infection
Keywords: Sofosbuvir SOF/GS-5816 GS-5816 Hepatitis C HCV Cirrhosis Velpatasvir
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 111
Healthy volunteers: no

Brief summary:
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of treatment with sofosbuvir/velpatasvir (SOF/VEL) in participants with chronic genotype 1, 2, 4, 6 or indeterminate HCV infection who received placebo in the Gilead-sponsored study GS-US-342-1138.

Detailed description:

Arms:
arm 1: SOF/VEL for 12 weeks

Interventions: intervention 1: SOF/VEL
Intervention descriptions: intervention 1: 400/100 mg tablet administered orally once daily

Protocol document: